United States News All stories

Shares of Eli Lilly (NYSE:LLY) rose 4% on Monday after the company unveiled highly anticipated clinical data for its next-generation obesity treatment, retatrutide.

Alphabet's Google (NASDAQ:GOOGL) has placed an order with Intel (NASDAQ:INTC) to manufacture more than 3 million of its custom artificial intelligence processors in 2028, according to a report from The Information cited by Reuters.

Amazon.com (NASDAQ:AMZN) has signed a multi-billion-dollar agreement with specialty glass maker Corning (NYSE:GLW) to expand the domestic production of optical fiber and connectivity products used to link modern data centers.

VinFast Auto (NASDAQ:VFS) reported a 41.7% increase in first-quarter revenue, boosted by a sharp rise in electric vehicle deliveries and aggressive international retail expansion.

Optical Cable (NASDAQ:OCC) reported a sharp turnaround in its second-quarter financial results for fiscal year 2026, driven by accelerating top-line growth and a substantial expansion of its product backlog.

Novo Nordisk (NYSE:NVO) announced that prescriptions for the oral version of Wegovy have exceeded 3 million since the product’s U.S. market introduction in January 2026.

Johnson & Johnson (NYSE:JNJ) announced today that it has entered into a definitive agreement to acquire Firefly Bio for $1 billion in cash.

MetaVia (NASDAQ:MTVA) has reported new data from its cardiometabolic pipeline at the American Diabetes Association’s (ADA) 2026 Scientific Sessions in New Orleans.

Neurocrine Biosciences (NASDAQ:NBIX) has announced new clinician-reported data highlighting the effectiveness of INGREZZA (valbenazine) in treating tardive dyskinesia (TD) among individuals with intellectual and developmental disabilities (IDD).

Galmed Pharmaceuticals (NASDAQ:GLMD) has entered into a definitive agreement to acquire Colospan, a commercial-stage medical device company specializing in gastrointestinal surgery solutions.

Ingredion (NYSE:INGR) announced on Monday a definitive agreement to acquire the UK-based ingredients specialist Tate & Lyle in an all-cash transaction.

Alliance Resource Partners (NASDAQ:ARLP) announced on June 8, 2026, that it has entered into definitive agreements to acquire general partner and limited partner interests in AllDale Minerals III, LP and AllDale Minerals IV, LP (collectively, “AllDale III & IV”) for approximately $206.2 million.

FOX (NASDAQ:FOX) has finalized a multi-year agreement with the National Football League to serve as a broadcast partner for NFL content in Mexico.

Seaport Therapeutics (NASDAQ:SPTX) announced its financial results for the first quarter ended March 31, 2026, marking a pivotal period of transition for the Boston-based biotech as it enters the public markets.

Incyte (NASDAQ:INCY) announced today that it has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for an upfront payment of $1.25 billion.

RedHill Biopharma (NASDAQ:RDHL) announced on June 8, 2026, that it has officially commenced recognition and enforcement proceedings in South Korea to collect on a final judgment awarded by the New York Supreme Court against Kukbo.

SUNation Energy (NASDAQ:SUNE) and Suniva announced on June 8, 2026, the signing of a definitive reverse merger agreement.

Graham (NYSE:GHM) announced its financial results for the fourth quarter and full fiscal year ended March 31, 2026, marking a period of record-setting performance for the Batavia, New York-based manufacturer.

AECOM (NYSE:ACM) announced today that it has been awarded a new contract to provide comprehensive architecture and engineering (A/E) services to the U.S. Department of Homeland Security (DHS).

Pfizer (NYSE:PFE) announced on June 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for HYMPAVZI® (marstacimab-hncq). The therapy is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A or B, both with and without inhibitors.

Aeries Technology (NASDAQ:AERT) announced its financial results for the fiscal year ended March 31, 2026, marking a pivotal year of transformation.

AstroNova (NASDAQ:ALOT), a global leader in specialized print technology solutions, reported financial results for its fiscal 2027 first quarter ended April 30, 2026.

Lyell Immunopharma (NASDAQ:LYEL) announced on Monday that it has amended its ongoing U.S. Phase 1 clinical trial for LYL273 to a Phase 1/2 design.

Shattuck Labs (NASDAQ:STTK) announced positive top-line results from its Phase 1 clinical trial of SL-325, a novel Death Receptor 3 (DR3) blocking antibody.